Resources Repository
-
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Priority Setting/Ethics | Preferences/Values | Government/Law | North America | Chronic Disease/Risk | Mental Health | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Health Systems | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Europe -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Government/Law | North America | Injuries/Accidents | Chronic Disease/Risk | Mental Health | Child/Nutrition | Costing Methods | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology -
ArticlePublication 2017Misinformation Lingers in Memory: Failure of Three Pro-Vaccination Strategies
People's inability to update their memories in light of corrective information may have important public …
People's inability to update their memories in light of corrective information may have important public health consequences, as in the case of vaccination choice. The authors compare three potentially effective strategies in vaccine promotion: (1) one contrasting myths vs. facts, (2) one employing fact and icon boxes, and (3) one showing images of non-vaccinated sick children. Beliefs in the autism/vaccines link and in vaccines side effects, along with intention to vaccinate a future child, were…
Preferences/Values | Decision Psychology | Government/Law | North America | Child/Nutrition | Infectious Diseases | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2017Increasing Vaccination: Putting Psychological Science into Action
Vaccination is one of the great achievements of the 20th century, yet persistent public health …
Vaccination is one of the great achievements of the 20th century, yet persistent public health problems include inadequate, delayed, and unstable vaccination uptake. Psychology offers three general propositions for understanding and intervening to increase uptake where vaccines are available and affordable. The first proposition is that thoughts and feelings can motivate getting vaccinated. Hundreds of studies have shown that risk beliefs and anticipated regret about infectious disease correlate reliably with getting vaccinated; low confidence in…
Preferences/Values | Decision Psychology | Government/Law | North America | Global Governance | Infectious Diseases | Social Determinants | Policy/Regulation | Culture/Society | Health/Medicine | Science/Technology | Global -
ArticlePublication 2013Nutritional Policy Changes in SNAP: A Microsimulation and Cost-Effectiveness Analysis
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) …
This analysis estimated the health effects and cost-effectiveness of banning or taxing sugar-sweetened beverages (SSBs) or subsidizing fruits and vegetables purchased with SNAP. The target population was adults in the U.S. and the time horizon was 10 years. Results showed that banning SSB purchases using SNAP benefits would be expected to avert 510,000 diabetes person-years and 52,000 deaths from MIs and strokes over the next decade, with a savings of $2900 per QALY saved. A…
Mathematical Models | Government/Law | North America | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Policy/Regulation | Economics/Finance | Food/Agriculture | Health/Medicine -
ArticlePublication 2019Health Impact and Cost-Effectiveness of SSB Taxes for Reducing Cancer Burden in the U.S.
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) …
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) tax policy for reducing obesity-related cancer in the U.S. A probabilistic cohort state-transition model, the Diet Cancer Outcome Model (DiCOM), was used to project the effect of a national $0.01 per ounce SSB excise tax on 13 obesity-associated cancers among U.S. adults age 20 and older over their lifetime. Cost-effectiveness was evaluated using both government affordability and societal perspectives. Results showed…
Mathematical Models | Government/Law | North America | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Policy/Regulation | Economics/Finance | Health/Medicine -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Benefit-Cost Analysis | Government/Law | North America | Chronic Disease/Risk | Costing Methods | Policy/Regulation | Health/Medicine